Glaucoma Research



Glaucoma is a disease in which damage to the optic nerve leads to the progressive, irreversible death of retinal cells and vision loss. Glaucoma is the second leading cause of blindness. The Glaucoma research team aims to fast track the translation of discoveries from the University of Birmingham research laboratories to improve outcomes for all patients with this debilitating degenerative condition.

Our research

Our ophthalmologists, psychiatrists, psychologists, neurologists, neuroscientists and bioengineers work together to develop a multi-disciplinary approach to research into glaucoma. We are pioneering advances in our understanding of the cellular and molecular events that underlie the disease to deliver excellence in innovation for the treatment of this complex disease to deliver excellence in innovation for the treatment of this complex disease.

Of special interest to the team is research that advances our understanding of the mechanisms responsible for retinal damage and the loss of retinal neurons during disease progression. Linked to this is the development of novel neuroprotective drugs that will help preserve the vision of glaucoma patients.

We also have a particular interest in developing a better understanding of the cause of the ocular hypertension that can develop in glaucoma and how new multi-modal drugs may help reduce ocular pressure and protect the retina from further damage.


  • Rescuing Retinal Ganglion Cells by Survival Signaling – Wellcome Trust funded project led by Dr Zubair Ahmed
  • Evaluating novel anti-fibrotic drugs that reduce ocular hypertension – BBSRC funded project led by Professor Ann Logan 

Recent Publications

Hill LJ, Ahmed Z and Logan A (2016) Perspective: Decorin treatment for reversing trabecular meshwork fibrosis in open-angle glaucoma. Neural Regeneration 11(6):922-3

Mead B, Hill LJ, Blanch RJ, Ward K, Logan A, Berry M, Leadbeater W and Scheven BA (2016) Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. Cytotherapy 18(4):487-96

Hill LJ, Mead B, Blanch RJ, Ahmed Z, De Cogan F, Morgan-Warren PJ, Mohamed S, Leadbeater W, Scott RA, Berry M and Logan A (2015) Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork. Invest Ophthalmol Vis Sci 56(6):3743-57

Vigneswara V, Esmaeili M, Deer L, Berry M, Logan A and Ahmed Z (2015) Eye drop delivery of pigment epithelium-derived factor-34 promotes retinal ganglion cell neuroprotection and axon regeneration. Mol Cell Neurosci 68:212-21

Mead B, Berry M, Logan A, Scott RA, Leadbeater W and Scheven BA (2015) Stem cell treatment of degenerative eye disease. Stem Cell Res 14(3):243-57

Mead B, Thompson A, Scheven BA, Logan A, Berry M and Leadbeater W (2014) Comparative evaluation of methods for estimating retinal ganglion cell loss in retinal sections and wholemounts. PLoS One 9(10):e110612

Mead B, Logan A, Berry M, Leadbeater W and Scheven BA (2014) Paracrine-mediated neuroprotection and neuritogenesis of axotomised retinal ganglion cells by human dental pulp stem cells: comparison with human bone marrow and adipose-derived mesenchymal stem cells. PLoS One 9(10):e109305

Mead B, Logan A, Berry M, Leadbeater W and Scheven BA (2014) Dental pulp stem cells, a paracrine-mediated therapy for the retina. Neural Regen Res 9(6):577-8

Vigneswara V, Berry M, Logan A and Ahmed Z (2012) Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats. PLoS One 7(12):e53473

Ahmed Z, Kalinski H, Berry M, Almasieh M, Ashush H, Slager N, Brafman A, Spivak I, Prasad N, Mett I, Shalom E, Alpert E, Di Polo A, Feinstein E and Logan A (2011) Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis 2:e173

Research Team